Aptinyx (APTX) Tops Q3 EPS by 5c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Aptinyx Reports Third Quarter 2020 Financial Results and Recent Highlights
November 12, 2020 4:03 PM ESTSignificant development progress across clinical-stage pipeline programs, with multiple clinical and regulatory milestones expected over the next 18 months
Recommenced patient recruitment in Phase 2b clinical study of NYX-2925 in patients with fibromyalgia
Near-term recommencements planned for Phase 2b clinical study in painful DPN and exploratory Phase 2 study in cognitive impairment
Reported positive results from exploratory Phase 2 clinical study of NYX-783 in patients with PTSD
Strengthened cash position through common stock offering, expected to provide operational runway into 2023... More
